1. Home
  2. NDSN vs VTRS Comparison

NDSN vs VTRS Comparison

Compare NDSN & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nordson Corporation

NDSN

Nordson Corporation

HOLD

Current Price

$309.83

Market Cap

16.0B

Sector

Industrials

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$16.23

Market Cap

18.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDSN
VTRS
Founded
1935
1961
Country
United States
United States
Employees
N/A
30000
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0B
18.7B
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
NDSN
VTRS
Price
$309.83
$16.23
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$320.80
$13.50
AVG Volume (30 Days)
264.5K
10.3M
Earning Date
05-27-2026
05-07-2026
Dividend Yield
1.17%
3.21%
EPS Growth
4.93
N/A
EPS
4.47
0.05
Revenue
$2,254,668,000.00
$14,299,900,000.00
Revenue This Year
$7.71
$4.41
Revenue Next Year
$4.96
$1.96
P/E Ratio
$69.06
$324.60
Revenue Growth
9.08
N/A
52 Week Low
$213.26
$9.43
52 Week High
$315.68
$18.39

Technical Indicators

Market Signals
Indicator
NDSN
VTRS
Relative Strength Index (RSI) 62.76 40.79
Support Level $279.86 $15.82
Resistance Level $315.68 $16.54
Average True Range (ATR) 5.34 0.52
MACD 0.37 -0.17
Stochastic Oscillator 76.13 12.75

Price Performance

Historical Comparison
NDSN
VTRS

About NDSN Nordson Corporation

Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets, including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.8 billion in revenue in its fiscal 2025.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: